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Ruth F. Dubin1, Suzanne Judd2, Rebecca Scherzer1, Michael Shlipak1, David G. Warnock3,
Mary Cushman4, Mark Sarnak5, Chirag Parikh6, Michael Bennett7, Neil Powe1 and
Carmen A. Peralta1
1Department of Medicine, University of California, San Francisco, San Francisco, California, USA; 2Department of Biostatistics,
University of Alabama at Birmingham, Birmingham, Alabama, USA; 3Department of Medicine, University of Alabama at Bir-
mingham, Birmingham, Alabama, USA; 4Department of Medicine, University of Vermont, Colchester, Vermont, USA;
5Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts, USA; 6Department of Medicine, Yale
School of Medicine, New Haven, Connecticut, USA; and 7Department of Pediatrics, Cincinnati Children’s Hospital, Cincinnati,
Ohio, USAIntroduction: Urinary neutrophil gelatinaseassociated lipocalin (uNGAL) and urinary kidney injury
molecule1 (uKIM-1) are established markers of subclinical acute kidney injury. In persons with reduced
estimated glomerular filtration rate (eGFR) and albuminuria who are at high risk for end-stage renal
disease (ESRD) and death, the associations of these urinary markers with incident ESRD or death is an area
of active investigation.
Methods: Among 1472 black and white participants from the REasons for Geographic and Racial Differ-
ences in Stroke (REGARDS) study with eGFR #60 ml/min per 1.73 m2 (Chronic Kidney Disease Epidemi-
ology Collaboration [CKD-EPI] cystatin, 2012) and albumin-to-creatinine ratio (ACR) $30 mg/g, we
evaluated the associations of baseline uNGAL and uKIM-1 with progression to ESRD and all-cause death.
Cox models were sequentially adjusted for urinary creatinine, traditional risk factors, C-reactive protein,
ACR, and eGFR.
Results: There were 257 ESRD events and 819 deaths over a median follow-up of 5.7 and 6.5 years,
respectively. In demographic adjusted models, higher levels of uNGAL were associated with increased risk
of ESRD and death, but these associations were attenuated in fully adjusted models including baseline
eGFR for both ESRD (hazard ratio [HR] ¼ 1.06 per doubling, 95% confidence interval [CI] 0.98–1.14) and
death (HR ¼ 1.04, 95% CI ¼ 1.00–1.08). Higher levels of uKIM-1 were associated with increased risk of ESRD
and death in demographic-adjusted models, and although attenuated in fully adjusted models, remained
statistically significant for both ESRD (HR ¼ 1.24 per doubling, 95% CI ¼ 1.08–1.42) and death (HR ¼ 1.10,
95% CI ¼1.03–1.19).
Conclusion: In this cohort of high-risk patients with baseline eGFR #60 ml/min per 1.73 m2 and albu-
minuria, renal tubular injury is associated with higher mortality and progression to ESRD. Further studies
are necessary to investigate the mechanism underlying this increased risk.
Kidney Int Rep (2018) 3, 1183–1192; https://doi.org/10.1016/j.ekir.2018.05.013
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).N eutrophil gelatinaseassociated lipocalin (NGAL)and the ectodomain of the receptor kidney injury
molecule1 (KIM-1) are rapidly released by renal
tubular epithelia following ischemic or toxic acute kid-
ney injury (AKI).1,2 Urinary levels of NGAL (uNGAL)
and KIM-1 (uKIM-1) are established as markers of acutespondence: Ruth F. Dubin, San Francisco VA Medical Center,
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International Reports (2018) 3, 1183–1192cellular injury within kidney tubules,3 and uKIM-1 is
associated with poor outcomes among patients with
AKI.4 With regard to biological function, NGAL has
anti-inflammatory and antibacterial effects due to its
capacity to sequester iron.3 In the setting of AKI, the
receptor KIM-1 facilitates phagocytosis of apoptotic
cells,5,6 but in chronic kidney disease, KIM-1 may
have pathogenic effects leading to interstitial fibrosis.7
Among individuals without CKD and any known AKI,
baseline uKIM-1 is associated with incident CKD,8 and
both uNGAL and uKIM1 are higher in patients with1183
CLINICAL RESEARCH RF Dubin et al.: uNGAL, uKIM-1 in CKD Patients of REGARDSCKD compared to patients with normal kidney func-
tion.9–12 Taken together, these observations suggest
that in the ambulatory setting, uNGAL and uKIM-1
are markers of ongoing tubular injury.
Following these observations, there have been
several epidemiological investigations of uKIM1 and
uNGAL as predictors of ESRD and mortality, but re-
sults have differed depending on the population
studied. For example, in a study of Pima Indians with
type 2 diabetes, higher uNGAL was independently
associated with long-term ESRD and mortality.13 In
kidney transplant recipients, uNGAL was an inde-
pendent risk factor for graft failure and mortality.14
Both uNGAL and KIM-1 were associated with overall
mortality in the Chronic Renal Insufficiency Cohort
(CRIC).15 However, neither uNGAL nor uKIM1 were
independently associated with CKD progression in
CRIC16 or in the community-based Atherosclerosis Risk
in Communities Study (ARIC).17 Thus, in patients with
stable CKD, whether elevated levels of uNGAL and
uKIM1 are associated with ESRD and all-cause mortal-
ity in large, community-based cohorts has not been
well established.
We designed this study to determine the importance
of tubular injury, as measured by uNGAL and uKIM-1,
with short-term and long-term risk for incident ESRD
and all-cause death among black and white community-
dwelling persons with impaired eGFR and albuminuria.
Because uNGAL and KIM1 are produced rapidly in
response to AKI, we hypothesized that they would have
stronger associations with short-term outcomes than
with long-term outcomes. We also hypothesized that
tubular marker associations would be stronger in par-
ticipants with more severe albuminuria, as elevations in
both markers would represent synergistic tubular and
glomerular injury. In addition, we examined whether
these associations were independent of baseline serum
markers of inflammation and renal function, as well as
traditional kidney disease risk factors.METHODS
REGARDS is a national cohort study designed to study
risk factors for stroke among black and white Ameri-
cans in the “stroke belt” of the United States. Between
2003 and 2007, a total of 30,239 participants aged 45
years or older were recruited to the study. Participant
information was first collected via telephone interview,
and a trained technician then conducted an in-home
examination for the anthropometric and physical ex-
amination, specimen collection, and medication
inventory.18
For these analyses, we included REGARDS partici-
pants (N¼ 1472) with eGFRcys#60 ml/min per 1.73 m21184(CKD-EPI 2012) and ACR ratio $30 mg/g at baseline.
We specified these inclusion criteria based on our prior
work in REGARDS, which has shown that these persons
are at highest risk for progression to ESRD and death.19
All appropriate institutional review boards approved
this study, and participants provided written informed
consent.
Outcomes
Incident ESRD was ascertained by linkage to the United
States Renal Data System (USRDS, www.usrds.org),
which maintains data on persons who initiate dialysis or
receive a kidney transplant. For these analyses, ESRD
status confirmed through linkage with USRDS was
updated through 2014. Deaths were reported by par-
ticipants’ proxies via telephone or mail, and were then
confirmedby review of death certificates or by linkage to
the Social Security Death Index.20 Deaths adjudicated
through February of 2016 were included in these
analyses.
Laboratory Methods
Urine samples were collected from participants during
in-home visits. Specimens were shipped on ice to a
central laboratory at the University of Vermont.21 All
urine specimens were in continuous storage thereafter
at 80C. NGAL and KIM-1 were measured at the
Cincinnati Children’s Hospital Medical Center
Biomarker Laboratory with the Bioporto Human NGAL
enzyme-linked immunosorbent assay (Bioporto, Hel-
lerup, Denmark) and with a KIM-1 assay kit developed
in-house, using Duoset (R&D Systems, Minneapolis,
MN) reagents.22 Coefficients of variation for uKIM-1
and uNGAL were 5.2% and 5.4%, respectively.
Urine albumin was measured by nephelometry using
the BNII ProSpec nephelometer (Dade-Behring, Deer-
field, IL) and urine creatinine by the Jaffe method us-
ing the Modular-P chemistry analyzer (Roche/Hitachi,
Basel, Switzerland) at the University of Vermont
laboratory. Serum creatinine was calibrated to
isotope dilution using mass spectrometrytraceable
methods,23 and Cystatin C was measured by particle-
enhanced immunonephelometry (N Latex Cystatin C
on the BNII, Formerly Dade Behring, Now Siemens AG,
Munich, Germany), as previously reported.19
Other Variables
Sociodemographic characteristics including age, race,
sex, income, education, smoking status, and alcohol use
were determined by self-report. Height and weight
were measured by a trained technician and used to
calculate body mass index (BMI). Hypertension was
defined by self-reported use of antihypertensive med-
ications or an average of 2 seated blood pressureKidney International Reports (2018) 3, 1183–1192
RF Dubin et al.: uNGAL, uKIM-1 in CKD Patients of REGARDS CLINICAL RESEARCHreadings (systolic blood pressure $140 mm Hg or
diastolic pressure$90 mm Hg). Diabetes was defined as
self-reported use of insulin or oral hypoglycemic
agents, fasting glucose $126 mg/dl, or nonfasting
glucose $200 mg/dl. High-density lipoprotein and
triglycerides were measured from fasting samples. The
eGFR was calculated using the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) 2012 equations
for creatinine, cystatin, and combined crea-
tininecystatin. eGFR cystatin was used as the inclu-
sion criteria, and the combined creatininecystatin
eGFR was used as a covariate in the multivariable
models.24
Analyses
We first compared baseline characteristics by tertile of
uNGAL concentration using the c2 and KruskalWallis
tests for categorical and continuous variables, respec-
tively.We then used Cox proportional hazardsmodels to
evaluate the association of each urinary biomarker with
the risk of ESRD or death in separate models. Because of
their right-skewed distributions, uNGAL and uKIM-1
were log transformed to normalize their distributions.
We modeled uNGAL and uKIM-1 as both continuous
(per doubling) and in tertiles. To determine whetherFigure 1. Cumulative incidence of end-stage renal disease (ESRD), by tert
kidney injury molecule1 (KIM-1), in REasons for Geographic and Racial Di
proportional hazards assumption found that the effect of NGAL tertile 3 (T3)
adjusted (P ¼ 0.31) analysis, whereas the effect of KIM T3 on ESRD risk
Kidney International Reports (2018) 3, 1183–1192each biomarker was independently associated with
ESRD or mortality, multivariable models were sequen-
tially adjusted for sociodemographic characteristics,
kidney disease risk factors, C-reactive protein, ACR, and
eGFR (CKD-EPI 2012 using creatinine and cystatin). We
additionally adjusted for urine creatinine, to account for
urine tonicity, and for ACR, to adjust for clinical evi-
dence of glomerular damage. For ESRD outcomes, we
conducted a sensitivity analysis for the competing risk
of death by applying the FineGray method.25 We
considered both short-term (within 2 years) and long-
term (within 10 years) outcomes, because we hypothe-
sized that these established kidney injury markers,
measured once at baseline, would have stronger associ-
ations with short-term outcomes than with long-term
outcomes (as observed in CRIC).26 In support of this
hypothesis, visual examination of the cumulative inci-
dence of ESRD suggested that uNGAL and uKIM1 had
associations with ESRD that varied over time (Figure 1).
Formal tests of the proportional hazards assumption
found that the effect of NGAL tertile 3 on ESRD risk
varied over time in unadjusted (P¼ 0.0003) but not fully
adjusted (P ¼0.31) analysis, whereas the effect of KIM
tertile 3 on ESRD risk varied over time only in fully
adjusted analysis (P ¼ 0.044).ile of urinary neutrophil gelatinaseassociated lipocalin (NGAL) and
fferences in Stroke (REGARDS) study participants. Formal tests of the
on ESRD risk varied over time in unadjusted (P ¼ 0.0003) but not fully
varied over time only in fully adjusted analysis (P ¼ 0.044).
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Table 1. Baseline characteristics of REGARDS participants stratified
by tertile of urinary NGAL
Parameter
Tertile of NGAL
P value1 (n [ 490) 2 (n [ 491) 3 (n [ 491)
Range of NGAL, ng/ml 0.1–26.4 26.5–81.4 81.5–5447
Age, yr 71 (64–77) 72 (64–78) 70 (63–78) 0.31
Female gender 145 (30%) 223 (45%) 310 (63%) <.0001
Race
Black 187 (38%) 251 (51%) 268 (55%) <.0001
White 303 (62%) 240 (49%) 223 (45%)
Income 0.0021
<$34k 248 (59%) 293 (68%) 27 (6%)
$35–74k 133 (32%) 109 (25%) 99 (23%)
$75k and above 41 (10%) 27 (6%) 25 (6%)
Diabetes mellitus 246 (51%) 230 (47%) 241 (49%) 0.55
Hypertension 419 (86%) 414 (85%) 422 (86%) 0.92
History of MI 206 (43%) 163 (34%) 168 (35%) 0.0091
History of stroke 59 (12%) 82 (17%) 80 (16%) 0.075
Cancer 83 (25%) 57 (17%) 62 (20%) 0.061
Current alcohol use 184 (38%) 177 (36%) 170 (35%) 0.24
Cigarette smoking 0.73
Current 75 (15%) 87 (18%) 78 (16%)
Past 217 (44%) 204 (42%) 203 (41%)
Never 196 (40%) 199 (41%) 209 (43%)
ASA 271 (55%) 256 (52%) 239 (49%) 0.11
Lipid-lowering Rx 239 (49%) 213 (44%) 213 (44%) 0.17
Systolic BP, mm Hg 134 (123–145) 137 (124–149) 134 (123–148) 0.14
Diastolic BP, mm Hg 78 (69–82) 79 (70–83) 78 (70–83) 0.39
BMI, kg/m2 29 (26–34) 29 (25–34) 30 (25–35) 0.42
Waist circumference, cm 103 (91–114) 102 (91–112) 100 (91–111) 0.092
LDL, mg/dl 99 (80–125) 106 (81–127) 104 (82–128) 0.13
HDL, mg/dl 42 (34–52) 44 (36–56) 45 (37–57) 0.0003
TG, mg/dl 136 (93–198) 126 (92–188) 130 (93–187) 0.20
CRP, mg/l 3.0 (1.4–5.9) 3.5 (1.5–8.6) 4.9 (1.9–9.9) <.0001
ACR, mg/g 94 (50–287) 105 (50–482) 142 (61–677) <.0001
eGFRcyscr 49 (39–57) 45 (34–55) 44 (30–53) <.0001
eGFRcys 43 (34–49) 40 (29–48) 37 (26–47) <.0001
eGFRcr 55 (45–68) 53 (38–66) 51 (35–63) <.0001
ACR, albumin-to-creatinine ratio; ASA, aspirin; BMI, body mass index; BP, blood pres-
sure; CRP, C-reactive protein; eGFRcr, estimated glomerular filtration rate creatinine;
eGFRcys, estimated glomerular filtration rate cystatin; eGFRcyscr, estimated glomerular
filtration rate creatinine-cystatin; HDL, high-density lipoprotein; LDL, low-density lipo-
protein; MI, myocardial infarction; NGAL, neutrophil gelatinaseassociated lipocalin;
REGARDS, REasons for Geographic and Racial Differences in Stroke; Rx, prescription;
TG, triglyceride.
Data are presented as median (interquartile range) or number (percentage).
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Baseline Characteristics
Among the 1472 participants included in these ana-
lyses, the overall mean ( SD) baseline age was 71
(9.3) years; median (interquartile range) eGFR by
CKD-EPI 2012, creatinine, and cystatin was 46 (3555)
ml/min per 1.73 m2; and median (interquartile range)
ACR was 113 (55417) mg/g. The median overall
eGFRcys was 40 ml/min per 1.73 m2 versus eGFRcr of
53 ml/min per 1.73 m2. The median level (interquartile
range) of uNGAL was 45 (21127) ng/ml, and the
median uKIM-1 was 886 (4701720) pg/ml. Partici-
pants in the highest tertile of uNGAL were more likely
to be female, African American, had lower income and
educational levels, and had higher levels of C-reactive
protein, albuminuria, and more advanced CKD, relative
to those with lower levels of uNGAL. There was little
difference across tertiles of NGAL for age, prevalence
of diabetes, smoking, and hypertension (Table 1).
Participants in the highest uKIM1 tertile were less
likely to be female or African American, more likely to
smoke, and had higher triglyceride levels, but did not
differ in socioeconomic status. As with uNGAL, par-
ticipants in the highest uKIM1 tertile had higher levels
of C-reactive protein, albuminuria, and more advanced
CKD (Table 2).
Correlations Among Biomarkers
In unadjusted analysis, uNGAL showed modest but
statistically significant positive correlations with both
uKIM-1 (r ¼ 0.23, P < .0001) and ACR (r ¼ 0.13,
P < .0001), and was negatively correlated with eGFR
(CKD-EPI 2012 cystatin and creatinine) (r ¼ 0.18,
P < .0001). By comparison, uKIM-1 was weakly posi-
tively correlated with both eGFR (r ¼ 0.056, P ¼ 0.03)
and ACR (r ¼ 0.092, P ¼ 0.0004).
Urinary NGAL, KIM-1, and ESRD
A total of 257 participants progressed to ESRD over a
median follow-up of 5.7 years. In demographic-adjusted
models, higher levels of uNGALwere associated with an
increased risk of both 2-year and 10-year ESRD (HR ¼
1.62 and HR ¼ 1.25 per doubling, respectively, both
P< .0001) (Table 3). These associations were attenuated
and no longer statistically significant in fully adjusted
models for both 2-year and 10-year ESRD (HR ¼ 1.19,
P ¼ 0.060, and HR ¼ 1.06, P ¼ 0.18, respectively).
Higher levels of uKIM-1 were also associated in
demographic-adjusted models with increased risks of
2-year and 10-year ESRD (HR ¼ 1.93 and 1.48 per
doubling, respectively, both P < .0001). These associa-
tions were attenuated in fully adjusted models for both
2-year ESRD (HR ¼ 1.21, P ¼ 0.34) and 10-year ESRD
(HR ¼ 1.24, P ¼ 0.0025). Applying the FineGray
1186analysis to account for the competing risk of death did
not substantially change these results. For example, for
NGAL, the HR of ESRD per doubling (95% CI) was 1.19
(0.991.42) and was 1.18 (0.991.41) using FineGray
analyses.
Urinary NGAL, KIM-1, and All-Cause Mortality
There were a total of 819 deaths over a median follow-
up period of 6.5 years. In demographic-adjusted
models, higher levels of uNGAL were associated with
an increased risk of both 2-year and 10-year death
(HR ¼ 1.20 and HR ¼ 1.09 per doubling, respectively,
both P < .0001) (Table 4). These associations were
attenuated but remained statistically significant in fullyKidney International Reports (2018) 3, 1183–1192
Table 2. Baseline characteristics of REGARDS participants,
stratified by tertile of urinary KIM-1
Parameter
Tertile of KIM-1
P value1 (n [ 490) 2 (n [ 491) 3 (n [ 490)
Range of KIM-1, pg/ml 15.8–587 589–1378 1380–28,631
Age, yr 71 (64–78) 71 (65–78) 70 (63–77) 0.38
Female gender 250 (51%) 213 (43%) 214 (44%) 0.025
Race
Black 273 (56%) 231 (47%) 201 (41%) <.0001
White 217 (44%) 260 (53%) 289 (59%)
Income 0.88
<$34k 289 (67%) 282 (66%) 276 (65%)
$35–74k 109 (25%) 117 (27%) 115 (27%)
$75k and above 31 (7%) 28 (7%) 34 (8%)
Diabetes mellitus 253 (52%) 232 (47%) 231 (47%) 0.29
Hypertension 427 (87%) 411 (84%) 416 (85%) 0.31
History of MI 164 (34%) 179 (37%) 194 (40%) 0.15
History of stroke 75 (15%) 71 (15%) 74 (15%) 0.93
Cancer 69 (22%) 78 (23%) 54 (17%) 0.094
Current alcohol use 163 (33%) 172 (35%) 196 (40%) 0.21
Cigarette smoking <.0001
Current 67 (14%) 60 (12%) 113 (23%)
Past 199 (41%) 227 (46%) 197 (40%)
Never 223 (46%) 203 (41%) 178 (36%)
ASA 259 (53%) 256 (52%) 251 (51%) 0.88
Lipid-lowering Rx 246 (51%) 209 (43%) 210 (43%) 0.020
Systolic BP, mm Hg 137 (124–147) 134 (123–146) 134 (122–147) 0.14
Diastolic BP, mm Hg 78 (70–83) 78 (70–82) 78 (70–83) 0.91
BMI, kg/m2 30 (26–34) 29 (25–34) 29 (25–35) 0.39
Waist circumference, cm 102 (91–112) 102 (91–112) 102 (91–114) 0.94
LDL, mg/dl 104 (80–127) 101 (80–125) 104 (83–128) 0.48
HDL, mg/dl 45 (37–55) 43 (35–54) 43 (35–53) 0.13
TG, mg/dl 124 (86–187) 131 (91–192) 139 (100–196) 0.0050
CRP, mg/l 3.5 (1.6–7.4) 3.4 (1.4–7.7) 4.4 (1.7–9.4) 0.0044
ACR, mg/g 94 (49–316) 116 (56–410) 136 (57–645) 0.0006
eGFRcyscr 46 (34–54) 45 (34–54) 48 (37–57) 0.0084
eGFRcys 40 (30–48) 39 (29–47) 41 (31–49) 0.059
eGFRcr 52 (38–65) 52 (38–64) 56 (42–69) 0.0029
ACR, albumin-to-creatinine ratio; ASA, aspirin; BMI, body mass index; BP, blood pres-
sure; CRP, C-reactive protein; eGFRcr, estimated glomerular filtration rate creatinine;
eGFRcys, estimated glomerular filtration rate cystatin; eGFRcyscr, estimated glomerular
filtration rate creatinine-cystatin; HDL, high-density lipoprotein; KIM-1, kidney injury
molecule1; LDL, low-density lipoprotein; MI, myocardial infarction; REGARDS, REasons
for Geographic and Racial Differences in Stroke; Rx, prescription; TG, triglyceride.
Data are presented as median (interquartile range) or number (percentage).
RF Dubin et al.: uNGAL, uKIM-1 in CKD Patients of REGARDS CLINICAL RESEARCHadjusted models for both 2-year and 10-year death
(HR ¼ 1.12, P ¼ 0.0091; and HR ¼ 1.04, P ¼ 0.043,
respectively). Higher levels of uKIM-1 were also asso-
ciated in demographic-adjusted models with increased
risks of 2-year and 10-year death (HR ¼ 1.40 and 1.21
per doubling, respectively, both P < .0001). These
associations were attenuated but remained statistically
significant in in fully adjusted models for both 2-year
and 10-year death (HR ¼ 1.23, P ¼ 0.016; and HR ¼
1.10, P ¼ 0.0080, respectively).
Interval Hazard Ratios for Biomarkers
We evaluated the associations of each biomarker with
the outcomes ESRD and mortality during each 2-year
time interval during the period of follow-up. TheKidney International Reports (2018) 3, 1183–1192hazard ratios for ESRD and mortality appeared to be
strongest in the first 2 years of follow-up, with a pro-
gressive weakening over time for both biomarkers
(Figure 2).
Interaction With Albuminuria
To address the hypothesis that the associations of the
urine markers with ESRD and mortality might differ by
severity of albuminuria, we tested interactions of KIM-
1 and NGAL with ACR on each outcome. The associa-
tion of KIM-1 with risk of ESRD appeared to be weaker
at higher levels of ACR (P¼ 0.0018, test for interaction,
Figure 3). For example, at an ACR of 30 mg/g, the
hazard ratio was 1.49 per doubling of KIM-1; this
hazard ratio fell to 1.16 at an ACR of 300 and to 1.01 at
an ACR of 1000. By contrast, the association of NGAL
with increased risk of ESRD appeared to be constant
across the range of ACR (P ¼ 0.40, test for interaction).
We also found statistically significant interactions of
KIM-1 by ACR (P ¼ 0.0080) and NGAL by ACR (P ¼
0.043) on mortality, but the differences in hazard ratios
at low and high levels of ACR were much more modest
than for ESRD. For example, the effect of KIM-1 on
mortality ranged from HR ¼ 1.06 to 1.16 at ACR levels
of 30 to 1000 mg/g, and the effect of NGAL on mor-
tality ranged from HR ¼ 1.00 to 1.08 at ACR levels of
30 to 1000. We performed additional tests for interac-
tion of NGAL and KIM-1 with age, black race, diabetes,
and C-reactive protein. There was a significant inter-
action of KIM-1 with black race for the outcome ESRD
(P ¼ 0.009, fully adjusted model), but no other sig-
nificant interactions were found.
DISCUSSION
In this cohort of black and white, older, community-
dwelling adults with CKD and albuminuria, uNGAL
and uKIM-1 were associated with all-cause mortality
independently of sociodemographic, comorbidities,
and baseline eGFR. Both KIM-1 and NGAL were asso-
ciated with ESRD in models that controlled for tradi-
tional risk factors. After further adjustment for eGFR,
KIM1 remained associated with ESRD, whereas NGAL
was no longer statistically significant. We also found
that the association of KIM-1 with ESRD was weaker at
higher levels of ACR.
Urinary Markers and ESRD
uKIM1 was associated with 10-year ESRD after
adjustment for traditional CKD risk factors and
eGFR(creatinine-cystatin [cr-cys]). In contrast, uNGAL
was associated with ESRD in models adjusted for
sociodemographics and comorbidities, but not after
adjustment for eGFR(cr-cys). Prior studies have
differed in regard to associations of these markers with1187
Table 3. Associations of urinary NGAL and KIM-1 with 2-year and 10-year progression to ESRD
ESRD events Model 1a HR (95% CI) Model 2b HR (95% CI) Model 3c HR (95% CI)
NGAL
ESRD at 2-year follow-up
NGAL T1 (reference) 5/483 (1%)
NGAL T2 versus T1 14/484 (3%) 3.25 (1.16–9.13) 2.04 (0.73–5.71) 1.19 (0.47–3.02)
NGAL T3 versus T1 37/484 (8%) 10.66 (3.81–29.82) 4.79 (1.65–13.88) 1.84 (0.66–5.15)
NGAL (per doubling) 56/1451 (4%) 1.62 (1.43–1.83) 1.45 (1.24–1.71) 1.19 (0.99–1.42)
ESRD entire follow-up period
NGAL T1 (reference) 54/483 (11%)
NGAL T2 versus T1 95/484 (20%) 2.36 (1.67–3.33) 1.86 (1.29–2.68) 1.41 (0.99–2.01)
NGAL T3 versus T1 108/484 (22%) 2.91 (2.02–4.20) 2.08 (1.43–3.02) 1.30 (0.89–1.90)
NGAL (per doubling) 257/1451 (18%) 1.25 (1.17–1.34) 1.18 (1.10–1.28) 1.06 (0.98–1.14)
KIM-1
ESRD at 2-year follow-up
KIM T1 (reference) 13/483 (3%)
KIM1 T2 versus T1 24/484 (5%) 3.68 (1.80–7.53) 1.99 (0.98–4.05) 1.50 (0.69–3.24)
KIM1 T3 versus T1 19/483 (4%) 4.78 (2.18–10.48) 1.41 (0.53–3.72) 1.09 (0.38–3.15)
KIM-1 (per doubling) 56/1450 (4%) 1.93 (1.51–2.46) 1.24 (0.86–1.79) 1.21 (0.82–1.77)
ESRD entire follow-up period
KIM T1 (reference) 78/483 (16%)
KIM1 T2 versus T1 91/484 (19%) 1.83 (1.33–2.51) 1.33 (0.95–1.86) 1.23 (0.88–1.72)
KIM1 T3 versus T1 88/483 (18%) 2.54 (1.78–3.64) 1.23 (0.83–1.84) 1.29 (0.85–1.96)
KIM-1 (per doubling) 257/1450 (18%) 1.48 (1.33–1.66) 1.13 (0.99–1.29) 1.24 (1.08–1.42)
CI, confidence interval; eGFRcr-cys, estimated glomerular filtration rate creatinine-cystatin; ESRD, end-stage renal disease; HR, hazard ratio; KIM-1, kidney injury molecule1; NGAL,
neutrophil gelatinaseassociated lipocalin, T1, tertile 1; T2, tertile 2; T3, tertile 3.
aModel 1: Age, sex, race, socioeconomic status, urine creatinine.
bModel 2: 1þ diabetes, systolic blood pressure, diastolic blood pressure, hypertension, smoking, body mass index, alcohol use, albumin-to-creatinine ratio, C-reactive protein.
cModel 3: 2þ eGFRcr-cys.
CLINICAL RESEARCH RF Dubin et al.: uNGAL, uKIM-1 in CKD Patients of REGARDSESRD. Neither uNGAL nor uKIM1 was independently
associated with CKD progression in the CRIC16 or
ARIC.17 In the Pima Indian study, uNGAL was asso-
ciated with ESRD, but uKIM1 was not.13 However,
uKIM1 has been shown to associate with progression to
ESRD in studies limited to specific CKD populations: for
example, in a cohort of diabetic patients undergoing
cardiopulmonary bypass27 and also a cohort of patients
with IgA nephropathy.28
The differences in associations of uKIM1 and
uNGAL with ESRD that we observed could be
accounted for by the different biological mechanisms of
production of uNGAL and uKIM1. Although uNGAL
and uKIM-1 are both produced as a result of renal
tubular injury, they differ in biological production,
function, and metabolism. uNGAL is secreted from
both proximal and distal renal tubular epithelial cells,
whereas KIM-1 is released from primarily proximal
tubular cells.29 Expression of renal epithelial KIM-1
causes interstitial fibrosis,7 whereas uNGAL is not
known to directly cause renal damage.
The associations of both uNGAL and KIM1 with
ESRD were strongest for events that occurred within
the first 2 years of biomarker measurement. The finding
of stronger associations for shorter-term ESRD may
reflect the within-subject variability of these markers.
A potential clinical application of this finding is that it1188may prove useful to use repeated measures of these
markers to evaluate short-term risk. Our findings are in
accordance with several studies of uNGAL in pop-
ulations with prevalent renal disease. In the CRIC
study, uNGAL had stronger associations with short-
term26 than long-term ESRD.16
It is also notable that in this REGARDS subcohort of
individuals with eGFR #60 ml/min per 1.73 m2 and
albuminuria, as well as in CRIC, the association of
uNGAL with ESRD was partially attenuated after
adjustment for comorbidities, ACR, and eGFR. There
are several potential explanations for this finding. One
interpretation is that uNGAL and eGFR convey over-
lapping information in relation to this outcome. In
support of this, uNGAL and eGFR showed a significant,
albeit modest, correlation. Another potential explana-
tion is that uNGAL reflects systemic NGAL levels, and
because systemic levels are filtered at the glomerulus,
the resultant uNGAL level may be explained by both
systemic levels and eGFR. It is noteworthy that some
studies have reported an association of uNGAL with
ESRD that was independent of comorbidities and eGFR,
including the Folic Acid for Vascular Outcome
Reduction in Transplantation Trial (FAVORIT) in kid-
ney transplant recipients,14 the Pima Indian study,13
and studies of pediatric patients with normal baseline
kidney function undergoing cardiac surgery.30 InKidney International Reports (2018) 3, 1183–1192
Table 4. Associations of urine NGAL and KIM-1 with 2-year and 10-year all-cause mortality
Mortality events Model 1a HR (95% CI) Model 2b HR (95% CI) Model 3c HR (95% CI)
NGAL
Mortality at 2-year follow-up
NGAL T1 (reference) 39/490 (8%)
NGAL T2 versus T1 44/491 (9%) 1.39 (0.89, 2.17) 1.07 (0.68, 1.69) 1.03 (0.65, 1.62)
NGAL T3 versus T1 67/491 (14%) 2.45 (1.61, 3.72) 1.73 (1.12, 2.68) 1.60 (1.03, 2.49)
NGAL (per doubling) 150/1472 (10%) 1.20 (1.11, 1.29) 1.13 (1.05, 1.23) 1.12 (1.03, 1.21)
Mortality entire follow-up period
NGAL T1 (reference) 252/490 (51%)
NGAL T2 versus T1 285/491 (58%) 1.33 (1.12, 1.58) 1.17 (0.98, 1.40) 1.12 (0.93, 1.33)
NGAL T3 versus T1 282/491 (57%) 1.45 (1.21, 1.74) 1.20 (1.00, 1.45) 1.13 (0.94, 1.37)
NGAL (per doubling) 819/1472 (56%) 1.09 (1.05, 1.13) 1.05 (1.02, 1.09) 1.04 (1.00, 1.08)
KIM-1
Mortality at 2-year follow-up
KIM1 T1 (reference) 41/490 (8%)
KIM1 T2 versus T1 48/491 (10%) 1.27 (0.82, 1.98) 1.09 (0.69, 1.72) 1.05 (0.67, 1.67)
KIM1 T3 versus T1 61/490 (12%) 2.38 (1.52, 3.73) 1.58 (0.97, 2.57) 1.62 (0.99, 2.66)
KIM-1 (per doubling) 150/1471 (10%) 1.40 (1.21, 1.63) 1.22 (1.03, 1.44) 1.23 (1.04, 1.47)
Mortality entire follow-up period
KIM1 T1 (reference) 260/490 (53%)
KIM1 T2 versus T1 277/491 (56%) 1.21 (1.01, 1.44) 1.05 (0.87, 1.26) 1.04 (0.87, 1.25)
KIM1 T3 versus T1 281/490 (57%) 1.58 (1.30, 1.92) 1.19 (0.96, 1.47) 1.23 (0.99, 1.51)
KIM-1 (per doubling) 818/1471 (56%) 1.21 (1.13, 1.29) 1.09 (1.01, 1.17) 1.10 (1.03, 1.19)
CI, confidence interval; HR, hazard ratio; KIM-1, kidney injury molecule1; NGAL, neutrophil gelatinaseassociated lipocalin; T1, tertile 1; T2, tertile 2; T3, tertile 3.
aModel 1: Age, sex, race, socioeconomic status, urine creatinine.
bModel 2: 1þ diabetes, systolic blood pressure, diastolic blood pressure, hypertension, smoking, body mass index, alcohol use, albumin-to-creatinine ratio, C-reactive protein.
cModel 3: 2þ eGFRcr-cys.
RF Dubin et al.: uNGAL, uKIM-1 in CKD Patients of REGARDS CLINICAL RESEARCHcontrast to this REGARDS study subgroup and the
CRIC cohort, participants in these studies had relatively
normal eGFR at baseline. uNGAL, a 25-kDa molecule, is
freely filtered at the glomerulus in the setting of normal
kidney function31; thus urinary levels may be deter-
mined largely by serum levels in patients with normal
renal function. uNGAL, a byproduct of neutrophil
activation, is higher in the setting of systemic inflam-
mation,32 for example, bacterial infection.33 In non-
renal, noninfectious disease, systemic inflammation
likely accounts for the associations of serum NGAL
with disease severity in inflammatory bowel disease34
or metastasis of colorectal cancer.35 For this reason,
we included C-reactive protein in our multivariable
models. Although the association of uNGAL with ESRD
was independent of C-reactive protein in our study, we
cannot exclude the possibility that systemic inflam-
mation may contribute to elevations in uNGAL.
Urinary Markers and Overall Mortality
In this REGARDS subcohort, uNGAL and uKIM-1 both
were associated with all-cause mortality, independently
of ACR and eGFR. This finding is in accordance with the
independent associations of uNGAL with mortality
among kidney transplant recipients,14 and the associa-
tions of both uNGAL and uKIM-1 with mortality in
CRIC.15 Studies in the Framingham cohort,36 and in the
Healthy Aging, Body and Composition (Health ABC)Kidney International Reports (2018) 3, 1183–1192cohort37 also demonstrated an association of uKIM-1
with mortality independent of eGFR. One way to inter-
pret these observations is that uNGAL or KIM-1 adds
information about renal disease that is distinct from
eGFR (e.g., sodium handling or water balance), and that
these associations confirm the adverse effects of renal
dysfunction on the heart and other organ systems.
However, in the case of uNGAL, it is also possible that
the associations with cardiovascular events or overall
mortality, independently of eGFR, are explained by the
influence of systemic inflammation on serum NGAL,
which in turn is filtered at the glomerulus. It is also
worth noting that the cohort comprised mostly partici-
pants more than 65 years of age, and there was a fairly
high frequency of death over 10 years (56%). Taken
together with the fact that eGFR estimates by cystatin
were substantially lower than eGFR by creatinine, and
that we did not measure “change in eGFR” as an
outcome, it is possible that in this relatively older, frail
population that death events may have preceded CKD
progression. However, we did not find substantive
changes in the hazard ratios when using FineGray
models to account for the competing risk of death.
Interactions With Albuminuria
We found that the association of KIM-1 with ESRD was
weaker at higher levels of ACR. This was contrary to
our hypothesis of the potential synergistic effect of the1189
Figure 2. Associations of neutrophil gelatinaseassociated lipocalin (NGAL) and kidney injury molecule1 (KIM-1) with risk of end-stage renal
disease (ESRD) and mortality, overall and by time in REasons for Geographic and Racial Differences in Stroke (REGARDS) study participants.
Figure illustrates the associations of each biomarker with the outcomes ESRD and mortality during each 2-year time interval during the period of
follow-up. The hazard ratios for ESRD and mortality appeared to be strongest in the first 2 years of follow-up, with a progressive weakening over
time for both biomarkers. Hazard ratios are per doubling of urinary marker, using multivariable adjusted models controlling for demographics,
socioeconomic status, diabetes mellitus, systolic blood pressure, diastolic blood pressure, hypertension, smoking, body mass index, alcohol
use, albumin-to-creatinine ratio, C-reactive protein, estimated glomerular filtration rate, and urine creatinine.
CLINICAL RESEARCH RF Dubin et al.: uNGAL, uKIM-1 in CKD Patients of REGARDS2 markers. This may be due to the well-known asso-
ciations between albuminuria and CKD progression,
rendering KIM-1 levels less relevant at higher levels of
ACR. Although the associations of both uNGAL and
uKIM-1 with mortality were somewhat stronger at
higher levels of ACR, the differences in hazard ratios
were very small. This was consistent with our
hypothesis that concomitant glomerular and tubular
damage may be additive in leading to adverse
outcomes.Figure 3. Assessment of biomarker interactions for 10-year progression
ratios (HRs) (with 95% confidence intervals [CIs]) are shown per
gelatinaseassociated lipocalin (NGAL) across the range of albumin-to
Cox (Death) models, controlling for demographics, socioeconomic sta
diastolic blood pressure (DBP), hypertension (HTN), smoking, body mass
glomerular filtration rate (eGFR), urine creatinine, plus interaction term
teractions of urinary ACR with each biomarker for the outcomes ESR
multivariable adjusted models controlling for demographics, SES, DM, S
urine creatinine.
1190Our study represents a large, diverse, community-
dwelling sample of adults with moderate CKD. The
REGARDS study performed in-home visits in 48 states
across the United States, which increases the general-
izability of the findings to the community. The cohort
represents a well-characterized population with 2
serum markers of renal function (i.e., creatinine and
cystatin C), urinary ACR, and 2 novel urinary markers
of tubular injury. There is long-term follow-up for the
clinical outcomes ESRD and mortality.to end-stage renal disease (ESRD) and all-cause mortality. Hazard
doubling of kidney injury molecule1 (KIM-1) and neutrophil
-creatinine ratios (ACRs). Estimates are from FineGray (ESRD) or
tus (SES), diabetes mellitus (DM), systolic blood pressure (SBP),
index (BMI), alcohol use, ACR, C-reactive protein (CRP), estimated
s for KIM-1by-ACR or NGAL-by-ACR. Figure illustrates the in-
D and mortality. HRs are per doubling of urinary marker, using
BP, DBP, HTN, smoking, BMI, alcohol use, ACR, CRP, eGFR, and
Kidney International Reports (2018) 3, 1183–1192
RF Dubin et al.: uNGAL, uKIM-1 in CKD Patients of REGARDS CLINICAL RESEARCHOur study also has certain limitations. The majority
of the cohort comprises patients more than 65 years of
age, and the discrepancy between cystatin- and
creatinine-based eGFR suggests that members of the
cohort were frail. Our findings may not generalize to a
younger, less frail population. We acknowledge that
the event rates for 2-year ESRD are lower than for
other outcomes, and thus confidence intervals are
wider for this outcome. We cannot determine the
extent to which systemic disease could influence this
association via serum NGAL filtered by the glomer-
ulus, and we lacked information about infectious dis-
ease in the cohort. Although the urinary specimens
were not processed immediately after voiding, and
although NGAL was measured after thaw, errors from
collection would bias our findings toward the null.
Kidney biopsy samples were not obtained, so we
cannot definitively ascertain the specific cause of
kidney disease. Incident ESRD was ascertained after
the patient had been on dialysis for 3 months;
although this increased our ability to discern ESRD
from AKI requiring dialysis, we may have missed
ESRD events in patients who died shortly after starting
dialysis.
In summary, uNGAL and KIM-1 were associated
with all-cause mortality independently of traditional
risk factors, ACR, and eGFR. Moreover, higher levels of
KIM-1 were associated with progression to ESRD.
These findings suggest that tubular injury may repre-
sent an important risk factor for complications,
including death and ESRD, for patients with CKD.
Future studies are warranted to elucidate mechanisms
to explain the observed associations.
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